JUBILANT PHARMOVA LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 6,059 | 6,282 | 6,703 | 7,235 | 8,280 |
| EBITDA (ex other income) | 1,085 | 719 | 732 | 1,533 | 1,201 |
| margin % | 17.9 | 11.5 | 10.9 | 21.2 | 14.5 |
| Owners' profit | 414 | (61) | 77 | 839 | 399 |
| EPS, as reported (₹) | 26.00 | (3.83) | 4.87 | 52.99 | 25.15 |
| ROE % · ROCE % | 7.8 · 9.4 | (1.2) · 2.2 | 1.3 · 4.3 | 13.4 · 11.5 | 5.6 · 6.4 |
| Debt / equity (x) | 0.55 | 0.63 | 0.63 | 0.39 | 0.45 |
| Cash from operations | 838 | 661 | 971 | 1,072 | 1,227 |
| Capex | (600) | (814) | (898) | (1,116) | (1,449) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,123 | 2,290 | 2,229 |
| Profit before tax | 145 | 131 | 206 | 155 | 190 | 94 | 176 | 86 |
| Net profit | 103 | 101 | 151 | 103 | 120 | 56 | 119 | 56 |
| EPS (₹) | 6.47 | 6.37 | 9.71 | 6.49 | 7.59 | 3.52 | 7.55 | 3.57 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Radiopharma | 3,690 | 44.0 |
| Allergy Immunotherapy | 796 | 9.5 |
| Contract Development and Manufacturing Organisation - Sterile Injectables | 1,420 | 16.9 |
| Contract Research, Development and Manufacturing Organisation | 954 | 11.4 |
| Generics | 774 | 9.2 |
| Unallocable corporate | 46 | 0.5 |
| CDMO- Sterile injectables | 393 | 4.7 |
| CRDMO | 311 | 3.7 |
| Unallocable Corporate | 13 | 0.2 |
| Total, before eliminations |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · USFDA gives VAI classification to Jubilant HollisterStier Spokane facility | regulatory legal | high | — | — |
| 1 Sept 2026 · GST Show Cause Notice from Mysore Tax Authority for FY 2022-23 | regulatory legal | high | — | — |
| 29 Aug 2026 · Newspaper notice on physical share relodgement and KYC updation | compliance | minimal | — | — |
| 28 Aug 2026 · Subsidiary gets Rs 105.5 Cr GST show cause notice | regulatory legal | high | — | — |
| 26 Aug 2026 · 48th AGM concludes; all resolutions passed with Rs 5 dividend approved | board shareholder meetings | low | — | — |
| 26 Aug 2026 · 48th AGM held; all 4 resolutions passed; Rs 5 dividend approved | board shareholder meetings | medium | — | — |
| 22 Aug 2026 · USFDA approves Line 3 at Spokane contract manufacturing facility | business updates | high | — | — |
| 17 Aug 2026 · Postal Ballot clears re-appointment of Bhartia brothers as MD and Jt MD | management changes | high | — | — |
| 17 Aug 2026 · Postal ballot results: Bhartia brothers re-appointed as MD and Jt MD | management changes | high | — | — |
| 11 Aug 2026 · Newspaper publication of Q1 FY27 financial results filed with exchanges | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 8,395 |
| 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 46.1 | 28.9 | 127 of 169 | 25% |
| P/B | 2.3 | 3.3 | 59 of 163 | 64% |
| ROCE | 4.7 | 10.8 | 128 of 183 | 30% |
| ROE | 5.6 | 10.4 | 118 of 171 | 31% |
| Debt / Equity | 0.5 | 0.1 | 137 of 171 | 20% |
| EBITDA margin | 12.0 | 17.5 | 108 of 165 | 35% |
| Revenue growth | 17.3 | 16.3 | 78 of 161 | 52% |
| Profit growth | (45.0) | 30.9 | 130 of 158 | 18% |
| Market cap | 16299 | 839 | 35 of 182 | 81% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
